2.6(top 20%)
impact factor
1.3K(top 20%)
papers
49.7K(top 10%)
citations
97(top 5%)
h-index
2.6(top 20%)
impact factor
1.5K
all documents
52.4K
doc citations
151(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics Journal2005962
2UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityPharmacogenomics Journal2002664
3Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's diseasePharmacogenomics Journal2006649
4Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapyPharmacogenomics Journal2001545
5Common VKORC1 and GGCX polymorphisms associated with warfarin dosePharmacogenomics Journal2005434
6Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugsPharmacogenomics Journal2011412
7Pharmacogenomics of human UDP-glucuronosyltransferase enzymesPharmacogenomics Journal2003386
8The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expressionPharmacogenomics Journal2001383
9Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parametersPharmacogenomics Journal2013380
10Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationPharmacogenomics Journal2007379
11A marker for Stevens-Johnson syndrome …: ethnicity mattersPharmacogenomics Journal2006367
12A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's diseasePharmacogenomics Journal2010351
13Integrating genotype and phenotype information: an overview of the PharmGKB projectPharmacogenomics Journal2001340
14HIBAG—HLA genotype imputation with attribute baggingPharmacogenomics Journal2014339
15Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesisPharmacogenomics Journal2008335
16Pharmacogenetics of warfarin: current status and future challengesPharmacogenomics Journal2007290
17A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression dataPharmacogenomics Journal2010249
18ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future researchPharmacogenomics Journal2007247
19Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughputPharmacogenomics Journal2003226
20Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic responsePharmacogenomics Journal2002221
21Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effectsPharmacogenomics Journal2013218
22Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell typesPharmacogenomics Journal2004213
23Role of polymorphic human CYP2B6 in cyclophosphamide bioactivationPharmacogenomics Journal2003200
24HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysisPharmacogenomics Journal2014199
25Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitusPharmacogenomics Journal2009198
26The human dopamine D4 receptor repeat sequences modulate expressionPharmacogenomics Journal2003194
27A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depressionPharmacogenomics Journal2002190
28An association study of 43 SNPs in 16 candidate genes with atorvastatin responsePharmacogenomics Journal2005190
29Sulfation through the looking glass—recent advances in sulfotransferase research for the curiousPharmacogenomics Journal2002189
30The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trialPharmacogenomics Journal2004188
31Genetic predictors of response to antidepressants in the GENDEP projectPharmacogenomics Journal2009188
32Pharmacogenetics and the concept of individualized medicinePharmacogenomics Journal2006187
33Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factorsPharmacogenomics Journal2004181
34Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?Pharmacogenomics Journal2017173
35Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control studyPharmacogenomics Journal2008171
36Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsPharmacogenomics Journal2010169
37Pharmacogenetics of the arylamine N-acetyltransferasesPharmacogenomics Journal2002167
38Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorderPharmacogenomics Journal2006165
39Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profilingPharmacogenomics Journal2001163
40A whole-genome association study of major determinants for allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese patientsPharmacogenomics Journal2013160
41Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatinPharmacogenomics Journal2012158
42Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemiaPharmacogenomics Journal2004152
43Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysisPharmacogenomics Journal2011152
44The expanding role of BDNF: a therapeutic target for Alzheimer's disease?Pharmacogenomics Journal2006150
45Clinical implications of pharmacogenomics of statin treatmentPharmacogenomics Journal2006150
46Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortexPharmacogenomics Journal2007148
47Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancerPharmacogenomics Journal2015148
48Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?Pharmacogenomics Journal2005143
49Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patientsPharmacogenomics Journal2003141
50The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapyPharmacogenomics Journal2010141